## Safi Shahda

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10887304/publications.pdf

Version: 2024-02-01

394421 454955 1,141 31 19 30 citations h-index g-index papers 31 31 31 2348 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2146-2161.	7.3	31
2	Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. Cancers, 2021, 13, 1975.	3.7	9
3	A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs, 2020, 38, 821-830.	2.6	59
4	Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5348-5357.	7.0	29
5	Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform. Cancers, 2020, 12, 3787.	3.7	27
6	A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i> -Paclitaxel and Gemcitabine in Advanced Solid Tumors. Oncologist, 2019, 24, 14-e10.	3.7	32
7	The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1083-1101.	7.3	46
8	Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer, 2019, 19, 468.	2.6	31
9	Social correlates of mental health in gastrointestinal cancer patients and their family caregivers: Exploring the role of loneliness. Supportive Care in Cancer, 2019, 27, 2077-2086.	2.2	15
10	Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Gastrointestinal Endoscopy, 2019, 89, 390-398.	1.0	68
11	A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer Journal of Clinical Oncology, 2019, 37, 249-249.	1.6	3
12	Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e229-e232.	2.3	3
13	Examining the effect of peer helping in a coping skills intervention: a randomized controlled trial for advanced gastrointestinal cancer patients and their family caregivers. Quality of Life Research, 2018, 27, 515-528.	3.1	29
14	Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. JCO Precision Oncology, 2018, 2, 1-11.	3.0	13
15	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers, 2018, 10, 403.	3.7	13
16	Three cachexia phenotypes and the impact of fatâ€only loss on survival in FOLFIRINOX therapy for pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 673-684.	7.3	98
17	Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clinical Cancer Research, 2018, 24, 6204-6211.	7.0	61
18	A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. American Journal of Gastroenterology, 2017, 112, 537-554.	0.4	123

#	Article	IF	CITATIONS
19	A systematic review of psychosocial interventions for colorectal cancer patients. Supportive Care in Cancer, 2017, 25, 2349-2362.	2.2	35
20	Myeloid sarcoma of the sigmoid colon: An unusual presentation of a rare condition. Digestive and Liver Disease, 2017, 49, 1280.	0.9	5
21	Positive changes among patients with advanced colorectal cancer and their family caregivers: a qualitative analysis. Psychology and Health, 2017, 32, 94-109.	2.2	61
22	A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer Journal of Clinical Oncology, 2017, 35, 3541-3541.	1.6	53
23	A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC) Journal of Clinical Oncology, 2017, 35, 362-362.	1.6	4
24	Impact of Nab–Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. , 2017, 37, 5533-5539.		13
25	Family caregiving challenges in advanced colorectal cancer: patient and caregiver perspectives. Supportive Care in Cancer, 2016, 24, 2017-2024.	2.2	61
26	Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2016, 15, 2722-2732.	4.1	91
27	Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Oncologist, 2016, 21, 664-665d.	3.7	11
28	GI-4000 in <i>KRAS </i> mutant cancers. Expert Opinion on Investigational Drugs, 2014, 23, 273-278.	4.1	4
29	Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 284-291.	0.8	25
30	Regorafenib: from bench to bedside in colorectal cancer. Expert Review of Clinical Pharmacology, 2013, 6, 243-248.	3.1	4
31	APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1–STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival. PLoS ONE, 2012, 7, e47462.	2.5	84